Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.40 |
| ▸ | CPS1 | P31327 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1286402 | 0.88 | CA12 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14634602 | 0.85 | CYP11B1 (0.46) | KMT2AALDH1A1MEN1MAPK1SMN1; SMN2 | |
| SCHEMBL16168945 | 0.85 | CA12 (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23218 | 0.84 | RAB9A (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL370408 | 0.83 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29809608 | 0.83 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL290040 | 0.79 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1963842 | 0.79 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL958654 | 0.78 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9221739 | 0.77 | ALOX15 (0.36) | KMT2AALDH1A1MAPTMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055371-A | Faster automated iterative C-C bond formation | 伊利诺伊大学评议会 | 2026-05-15 | — | — | CN | disclosed |
| US-11932601-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| CN-117164499-A | Substituted benzofurans, benzopyrroles, benzothiophenes and structurally related complement inhibitors | 拜奥克里斯特制药公司 | 2023-12-05 | — | — | CN | disclosed |
| CN-112272553-B | Substituted benzofurans, benzopyrroles, benzothiophenes and structurally related complement inhibitors | 拜奥克里斯特制药公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-116390915-A | Aromatic compound, preparation method and application thereof | 杭州多域生物技术有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-116265468-A | Organic electroluminescent material and device | 环球展览公司 | 2023-06-20 | — | — | CN | disclosed |
| CN-113861188-B | Pyrazolo [3,4-b ] pyridine derivative, preparation method thereof and application thereof as HPK1 inhibitor | 杭州医学院 | 2023-02-28 | — | — | CN | disclosed |
| CN-115477676-A | Organic electroluminescent material and device | 环球展览公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-115279760-A | Novel HPK1 inhibitor and preparation method and application thereof | 轶诺(浙江)药业有限公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220274926-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2022-09-01 | — | — | US | disclosed |
| EP-3215141-A2 | IMMUNOREGULATORY AGENTS | Flexus Biosciences, Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016073738-A2 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| EP-2694472-A2 | SULFONAMIDE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012137982-A9 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-14 | — | — | WO | disclosed |
| WO-2012137982-A2 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-11 | — | — | WO | disclosed |
| US-20120088737-A2 | NOVEL ACYL GUANIDINE DERIVATIVES | AJINOMOTO CO., INC (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20110082109-A1 | NOVEL ACYL GUANIDINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2011-04-07 | — | — | US | disclosed |
| US-RE39679-E1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1192165-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000077010-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082109-A1 | NOVEL ACYL GUANIDINE DERIVATIVES | SLC9A3, NHERF1, SLC9A2 | CA12 3954/4885CA1 3641/4885CA2 516/4885 |
| US-20120088737-A2 | NOVEL ACYL GUANIDINE DERIVATIVES | SLC9A3, NHERF1, SLC9A2 | CA12 3954/4885CA1 3641/4885CA2 516/4885 |
| US-11932601-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | CA12 1645/4885CA1 1848/4885CA2 2550/4885 |
| US-20220274926-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | CA12 1645/4885CA1 1848/4885CA2 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.